Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Leases: 2016-2024

Historic Current Leases for ImmunityBio (IBRX) over the last 9 years, with Dec 2024 value amounting to $7.5 million.

  • ImmunityBio's Current Leases rose 4.02% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 4.02%. This contributed to the annual value of $7.5 million for FY2024, which is 42.37% up from last year.
  • Latest data reveals that ImmunityBio reported Current Leases of $7.5 million as of FY2024, which was up 42.37% from $5.2 million recorded in FY2023.
  • ImmunityBio's Current Leases' 5-year high stood at $7.5 million during FY2024, with a 5-year trough of $2.6 million in FY2022.
  • In the last 3 years, ImmunityBio's Current Leases had a median value of $5.2 million in 2023 and averaged $5.1 million.
  • Its Current Leases has fluctuated over the past 5 years, first crashed by 39.96% in 2021, then surged by 97.89% in 2023.
  • Over the past 5 years, ImmunityBio's Current Leases (Yearly) stood at $5.0 million in 2020, then crashed by 39.96% to $3.0 million in 2021, then dropped by 11.99% to $2.6 million in 2022, then skyrocketed by 97.89% to $5.2 million in 2023, then soared by 42.37% to $7.5 million in 2024.